Two Cases of Possible Exacerbation of Chronic Rejection After Anti-SARS-CoV-2 Messenger RNA Vaccination: A Case Report

In post–liver transplant recipients, SARS-CoV-2 infection is a health threat, and novel messenger RNA vaccines such as Pfizer BioNTech BNT162b2 and Moderna mRNA-1273 are aggressively recommended. However, there are few reports on their adverse effects, some of which may be potentially fatal. We have...

Descripción completa

Detalles Bibliográficos
Autores principales: Okamoto, Tatsuya, Okajima, Hideaki, Ogawa, Eri, Uebayashi, Elena Yukie, Yamamoto, Miki, Kadohisa, Masashi, Yamada, Yosuke, Minamiguchi, Sachiko, Haga, Hironori, Hatano, Etsurou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708617/
https://www.ncbi.nlm.nih.gov/pubmed/36572611
http://dx.doi.org/10.1016/j.transproceed.2022.11.009
Descripción
Sumario:In post–liver transplant recipients, SARS-CoV-2 infection is a health threat, and novel messenger RNA vaccines such as Pfizer BioNTech BNT162b2 and Moderna mRNA-1273 are aggressively recommended. However, there are few reports on their adverse effects, some of which may be potentially fatal. We have experienced 2 post–liver transplant recipients with exacerbated chronic rejection after vaccination, one of whom had to undergo retransplant and the other who is still in the process of liver function without improvement. These alarming cases will be presented as case reports.

Ejemplares similares